Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan 21;21(3):794-802.
doi: 10.3748/wjg.v21.i3.794.

PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis

Li-Zhen Chen  1 , Yong-Ning Xin  1 , Ning Geng  1 , Man Jiang  1 , Ding-Ding Zhang  1 , Shi-Ying Xuan  1
Affiliations
Review

PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis

Li-Zhen Chen et al. World J Gastroenterol. .

Abstract

Patatin-like phospholipase domain-containing 3 (PNPLA3 or adiponutrin) displays anabolic and catabolic activities in lipid metabolism, and has been reported to be significantly associated with liver fat content. Various studies have established a strong link between the 148 isoleucine to methionine protein variant (I148M) of PNPLA3 and liver diseases, including nonalcoholic fatty liver disease (NAFLD). However, detailed demographic and ethnic characteristics of the I148M variant and its role in the development of nonalcoholic fatty liver fibrosis have not been fully elucidated. The present review summarizes the current knowledge on the association between the PNPLA3 I148M variant and NAFLD, and especially its role in the development of nonalcoholic fatty liver fibrosis. First, we analyze the impact of demographic and ethnic characteristics of the PNPLA3 I148M variant and the presence of metabolic syndrome on the association between PNPLA3 I148M and NAFLD. Then, we explore the role of the PNPLA3 I148M in the development of nonalcoholic fatty liver fibrosis, and hypothesize the underlying mechanisms by speculating a pro-fibrogenic network. Finally, we briefly highlight future research that may elucidate the specific mechanisms of the PNPLA3 I148M variant in fibrogenesis, which, in turn, provides a theoretical foundation and valuable experimental data for the clinical management of nonalcoholic fatty liver fibrosis.

Keywords: Nonalcoholic fatty liver disease; Nonalcoholic fatty liver fibrosis; PNPLA3 I148M variant; Polymorphism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Simplified schematic model showing the hypothetical molecular mechanism by which the PNPLA3 I148M variant participates in the development and progression of nonalcoholic fatty liver fibrosis. The hedgehog signaling pathway links PNPLA3 with the activation of hepatic stellate cells, which is considered as the central part of fibrogenesis. PNPLA3 protein exhibits activities of lysophosphatidic acid acyltransferase and acylglycerol hydrolase to maintain the TG balance in the liver. The “gain function” of the PNPLA3 I148M variant causes Triglyceride (TG) accumulation in the liver, which accelerates the progression of nonalcoholic fatty liver disease. HSC: Hepatic stellate cell.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gao X, Fan JG. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes. 2013;5:406–415. - PMC - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609. - PubMed
    1. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des. 2013;19:5169–5176. - PubMed
    1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344. - PubMed
    1. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res. 2009;50 Suppl:S412–S416. - PMC - PubMed

Publication types

MeSH terms